DrugPatentWatch Database Preview
Duvelisib - Generic Drug Details
What are the generic drug sources for duvelisib and what is the scope of freedom to operate?
Duvelisib
is the generic ingredient in one branded drug marketed by Verastem Inc and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Duvelisib has one hundred and thirty patent family members in thirty countries.
One supplier is listed for this compound.
Summary for duvelisib
| International Patents: | 130 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 55 |
| Clinical Trials: | 22 |
| Patent Applications: | 146 |
| Drug Prices: | Drug price trends for duvelisib |
| DailyMed Link: | duvelisib at DailyMed |
Recent Clinical Trials for duvelisib
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Verastem, Inc. | Phase 2 |
| National Cancer Institute (NCI) | Phase 2 |
| OHSU Knight Cancer Institute | Phase 2 |
Synonyms for duvelisib
| (S)-3-(1-((9H-Purin-6-yl)amino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one |
| (S)-3-(1-(7H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one |
| (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one |
| 1(2H)-Isoquinolinone, 8-chloro-2-phenyl-3-((1S)-1-(9H-purin-6-ylamino)ethyl)- |
| 1(2H)-Isoquinolinone, 8-chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl]- |
| 1201438-56-3 |
| 610V23S0JI |
| 8-Chloro-2-phenyl-3-((1S)-1-(7H-purin-6-ylamino)ethyl)isoquinolin-1(2H)-one |
| A12422 |
| AB0032504 |
| AC-30239 |
| AJ-128213 |
| AK145604 |
| AKOS022186370 |
| AOB87713 |
| AS-16309 |
| AX8268013 |
| BC600328 |
| BCP07042 |
| BDBM50193013 |
| CHEBI:131169 |
| CHEMBL3039502 |
| compound 4904 [Patent US8193182] |
| Copiktra |
| Copiktra (TN) |
| CS-0888 |
| D10555 |
| DB11952 |
| DTXSID80152697 |
| Duvelisib (IPI-145 INK1197) |
| Duvelisib (IPI-145, INK1197) |
| Duvelisib (USAN/INN) |
| Duvelisib [USAN:INN] |
| EX-A1562 |
| GTPL7795 |
| HY-17044 |
| INK-1147 |
| INK-1197 |
| INK-1197|||IPI-145|||8-Chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one |
| INK1197 |
| IPI 145 |
| IPI-145 |
| IPI-145 (INK1197) |
| IPI-145 pound>>Duvelisib |
| ipi-145-ink1197 |
| IPI-145, INK 1197, Duvelisib |
| IPI145 |
| KS-0000062P |
| MFCD15144635 |
| NCGC00351482-01 |
| QC-10232 |
| s7028 |
| SB16470 |
| SCHEMBL153543 |
| SCHEMBL18343557 |
| SCHEMBL19670020 |
| SCHEMBL20580104 |
| SJVQHLPISAIATJ-ZDUSSCGKSA-N |
| ST24036081 |
| SW219822-1 |
| SYN1175 |
| UNII-610V23S0JI |
| W-5592 |
| X5816 |
| ZINC88346058 |
US Patents and Regulatory Information for duvelisib
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verastem Inc | COPIKTRA | duvelisib | CAPSULE;ORAL | 211155-002 | Sep 24, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Verastem Inc | COPIKTRA | duvelisib | CAPSULE;ORAL | 211155-002 | Sep 24, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Verastem Inc | COPIKTRA | duvelisib | CAPSULE;ORAL | 211155-002 | Sep 24, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for duvelisib
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Brazil | PI0906473 | Start Trial |
| European Patent Office | 3441392 | Start Trial |
| European Patent Office | 3238722 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
